Meet Our Team
Meet Our Team
Principle Investigator
Dr. Valliant is Founder and Chief Executive Officer of Fusion Pharmaceuticals. John has been instrumental in securing both investment and scientific and medical collaborations with the industrial and academic partners of Fusion.
Prior to Fusion, Dr. Valliant founded the Centre for Probe Development and Commercialization (CPDC), a radiopharmaceutical research and development centre of excellence established in 2008 through funding from the Federal and Provincial governments, industry and academic partners.
Principle Investigator
Dr. Sadeghi graduated from University of Toronto, Engineering Science program and received his Ph. D. from U of Toronto in analytical/physical chemistry as an NSERC scholar in 2008. He was a postdoctoral fellow at UCLA Crump institute 2009-2011. Prior to joining McMaster University, Dr. Sadeghi was an associate professor in the department of Molecular and Medical Pharmacology at UCLA, where he maintains an adjunct position. He has a background in managing a GMP compliant facility and research in radiochemistry, radiopharmaceutical development and validation, electrochemistry, microfluidics and instrumentation.
Dr. Sadeghi serves on peer review panels and has been a cofounder and an independent scientific and engineering consultant to several startups and small companies. He has previously served as the director of the Ahmanson Biomedical Cyclotron Facility at UCLA, which produces a wide variety of clinical position emission tomography tracers, and facilitates the clinical translation of successful research radiopharmaceuticals.
Principal Investigator
Dr. Inkster is a synthetic organic chemist and radiochemist with degrees from Simon Fraser University (MSc, PhD). His PhD research was completed at TRIUMF, Canada’s National Laboratory for Nuclear & Particle Physics in Vancouver. After post-doctoral studies at Les Hôpitaux Universitaires de Genève in Switzerland, James held joint appointments at Boston Children’s Hospital as a Research Associate (Division of Nuclear Medicine & Molecular Imaging) and Harvard Medical School (Radiology) as a Research Fellow. In 2021, James returned to Canada to join Prof. Eric Price’s lab in the University of Saskatchewan Dept. of Chemistry as a Research Associate.
Central to Dr. Inkster’s research is the discovery of innovative and broadly useful radio-labelling and radio-bioconjugate strategies, which he has leveraged towards the development of PET radiotracers for imaging cancer, cardiovascular disease, and Parkinsonian disorders. Current interests lie in the synthesis of molecular imaging agents targeting bacterial infections and beta cell function.
Research Scientist
Afaf received her PhD degree in organic chemistry with Professor Detlef Gabel, University of Bremen, Germany. Her doctoral work focused on the synthesis of organoboron compounds for BNCT. She spent a period of post-doctoral research with professor Hiroyuki Nakamura, Tokyo Institute of Technology. She started her work with Valliant Group at Mac in 2011. Currently, she is a research scientist in MRG and working towards the discovery and development of novel molecular imaging probes for use in pre-clinical studies of cancer therapy and diagnosis. Dr. Genady is also overseeing the projects’ executions, ensuring compliance with safety protocols, and providing guidance to the teamwork. With a deep understanding of the technical aspects, regulatory requirements, and industry standards associated with radiopharmaceutical development, Dr. Genady brings a wealth of knowledge that is essential for MRG.
Research Associate
Mohamed obtained his PhD in Germany at the Bremen University working on the development of boron-neutron capture cancer therapeutics. He worked as postdoctoral fellow/Scientific visiting professor in both Bremen University in Germany and at Gakushuin University in Tokyo, Japan (JSPS Fellow). He joined the Valliant group as postdoctoral fellow focusing on radiopharmaceutical chemistry. He worked as an associate researcher with Dr. Humphrey Fonge, at the University of Saskatchewan. Currently, he is a research associate in the MRG at McMaster University, working towards the discovery and development of novel molecular imaging compounds for use in pre-clinical drug studies for cancer therapy and diagnosis.
Laboratory Technician (Biology)
Rafael completed a B.Sc in Biochemistry at Sherbrooke University and a M.Sc. in Experimental Health Sciences at INRS University (Laval QC). His professional background includes Research Assistant positions with GIOSTAR Chicago (Glenview IL), Rosalind Franklin University (North Chicago IL) and MangoGen Pharma (Montreal QC). He contributes with his expertise in in vivo procedures in murine models, PET imaging, standard molecular biology techniques, aseptic cell culture and in the development and optimization of immuno-assays and cell-based assays.
Laboratory Technician (Biology)
Nic has completed an OCAD in Advanced Biotechnology & Forensics at Sir Stanford Fleming college, as well as B. Scs for Molecular Biology & Genetics and Biomedical sciences at the University of Guelph. Nic’s professional background includes Rodent Research Technician with Transpharmation (Fergus ON), Genetic Toxicology Analyst for Charles River Laboratories (Senneville QC), Mobile Laboratory Technician at LifeLabs (Guelph, ON), and a Research Laboratory Technician at Toronto General Hospital within the Latner Thoracic Research Laboratories (Toronto, ON). Nic contributes with expertise in advanced molecular biological techniques, aseptic cell work, in vivo procedures with rodents, imaging studies, and towards the optimization & development of new biological assays in the laboratory.
Postdoctoral Fellow, Biology
Dr. Ayman A. Ibrahim is a visiting postdoctoral scholar at McMaster University under the supervision of Dr. Saman Sadeghi. Ayman finished his Ph.D in Pharmacology & Toxicology at Faculty of Pharmacy, Cairo University, Egypt (2019). He also received his master’s degree in 2016 from Zagazig University, Egypt. Noteworthy, he has a strong experience in Quality control, Quality assurance, GMP and production of 99Mo/99mTc, 131I, 125I & 51Cr radiopharmaceuticals.
Generally, his main scientific interests are pharmacodynamics and pharmacokinetics of novel radiopharmaceuticals used in diagnosis and therapy & development of new treatment strategies against multiple diseases induced by ionizing radiation.
PhD Student
Pamela completed her undergraduate degree in Chemistry in 2018 at New York University before moving back to Nigeria to serve in the National Youth program for recent graduates. During the program, she worked as a laboratory assistant in an analytical chemistry lab and as a research assistant in the Centre for Applied Research on Separation Sciences.
PhD Student
Shirley obtained her undergraduate degree in Chemical Biology at the McMaster University in 2021. During her 4th thesis year, she worked on the synthetic pathway of lactone-based Pramanicin analogs. Upon graduating from McMaster, Shirley began her Master's degree in Chemical Biology at McMaster University in 2022 Winter, where she worked with Dr. Sam Sadeghi on Electrolysis and Nucleophilic Radio-fluorination substitution.
PhD Student
Shayan, graduated as a chemical engineer from Sharif University of Technology (Tehran), has started his studies since May 2023 at McMaster. As a Biomedical Engineering PhD student, his research focuses on radiotracer production in small volume reactors and microfluidic fabrication under the supervision of Dr. Sadeghi and Dr. Selvaganapathy.
PhD Student
Yusra completed her undergraduate degree in Chemical Biology in 2022 at McMaster University, during her 4th year, she completed her thesis in our lab, where she worked on the synthesis of novel dyes for photoacoustic imaging. Upon graduation, she worked as a biology laboratory assistant in the group. She started her master’s degree in the Fall of 2022, under the supervision of Dr. Sadeghi, where she focused on the development of Molecularly Targeted Photoacoustic Imaging agents. 2024 marked the beginning of her studies towards a PhD in Chemical Biology.
PhD Student
Carol completed her undergraduate Honours Chemical Biology degree at McMaster in 2024. She worked in our lab as an Audrey Cameron Academic Excellence Award (ACAEA) scholarship winner in Summer 2023/2024 and throughout her undergraduate thesis. She joined our group as a PhD student in Fall 2024. Her work focuses on developing and fine tuning various FAP inhibitor (FAPI) ligands that have the potential for applications in cancer radiotheranostics. In her free time, she enjoys exploring the outdoors, visiting cute cafes, snowboarding and playing volleyball!
MSc Student
Laiba completed her Undergraduate degree at the University of Toronto Mississauga with a double major in chemistry and health science, where she was able to fulfil a senior thesis that allowed her work on the interface of both medicinal and biological chemistry. Via SARs, Laiba was able to work towards modulating the reactivity of functionalized moieties by chemically tuning molecular scaffolds with a goal to produce a potent, isoform-selective inhibitor with improved pharmacokinetics. Laiba will continue her journey in drug discovery at McMaster University within the chemical Biology department in the Sadeghi Lab, where she will be working towards exploring the response of PMSA when manipulated with bifunctional radiotherapeutics for protein degradation. In her free time, Laiba enjoys spending time in nature and exploring new cafes within the city.
MSc Student
Kevina completed her undergraduate degree in Chemical Biology (Co-op) in 2023 at McMaster University. During her 4th year, she completed a thesis in the MRG lab related to Al[18F] radiolabeling. She then went on to complete a co-op with STEMCELL Technologies in Vancouver where she worked on the characterization of chemically modified polymers. Upon graduation, she has since returned to McMaster for her M.Sc. in Chemical Biology under the supervision of Dr. Inkster. Her project focuses on the development of novel SiFA-ylated peptide-based cancer imaging agents and translation to automated radiosynthesis.
MSc Student
Marwan is a chemical biology undergraduate who has joined our lab to complete his 4th year thesis. His research focusses on the use of DNA intercalators as potential enhancements to traditional radiopharmaceutical drugs by allowing them to bind to cancerous cell DNA and increase cytotoxicity. Other than chemistry, his hobbies include building computers, playing minesweeper, and cooking!.
MSc Student
My name is MingJie (Felix) Gong, and I am a graduate student in Medical and Biological Physics. My research focuses on Boron Neutron Capture Therapy (BNCT), and I am passionate about contributing to advancements in cancer treatment through this innovative therapy. I hope to make a meaningful difference in the field of BNCT and pushing the boundaries of what I can achieve in this area. In my free time, I enjoy watching old movies and spending time with furry animals. I’m currently raising a cat (ToTou), who brings a lot of joy to my life.
MSc Student
Ana completed her undergraduate degree in Chemical Biology (Co-op) at McMaster University in 2024. Her undergraduate thesis was on the synthesis of heterobifunctional PEG linkers supervised by Prof. James McNulty. She went on to work as a co-op student at CAMH where she was first introduced to radiochemistry. With newly gained interest in nuclear medicine, Ana chose to enter graduate studies in the McMaster Radiochemistry Group. Her current research is focused on developing radioimmunoconjugates for cancer therapy.
MSc Student
Waseem completed his undergraduate degree in Chemical Biology in 2024. He finished a research practicum during his final year with Dr. McNulty's group, in which he synthesized an aniline derivative and performed stepwise nucleophilic substitution on cyanuric chloride. After graduating, he joined Dr. Sadeghi's group as a Summer volunteer and remained in the group to complete his Master's in Chemical Biology. His research focuses on combining different radioisotopes into the same therapy for treating prostate cancer.
Undergraduate Student
Ana Rohan is completing his Chemical Biology Co-op Degree at McMaster University. His first coop was at Canadian Nuclear Laboratories investigating the effects of uranium contaminated drinking water in rats. He gained a passion for the nuclear sciences ever since, joining Dr. Sadeghi’s lab for his fourth year thesis in September 2024. His project, mentored by Masters student Marwan El-Ashiri, involves the chemical synthesis of a novel theranostic probe for prostate cancer. Aiming to combine a DNA intercalating moiety with either Lu-177 therapy or Ga-68 PET imaging. Aside from chemistry, Rohan enjoys piano, playing video games, and riding his motorcycle.
Undergraduate Student
Maya is an undergraduate student in the Integrated Science program, concentrating in Chemical Biology. She first joined Dr. Inkster’s lab through the CNL undergraduate summer research experience, during which she worked with graduate student Kevina Chavda on the development of SiFA-ylated peptide-based cancer imaging agents. Inspired by nuclear medicine, Maya continued as a research student in the lab, with her current project involving the development of novel 18F-labelled rhodamine derivatives for applications in cardiovascular imaging. In her free time, Maya enjoys painting, baking, and spending time with her cat.
Dr. Paul Schaffer graduated from the University of British Columbia in 1998 with a BSc in chemistry and biochemistry, followed by a Ph.D. in Chemistry from McMaster University in 2003. His doctoral work focused on the design and synthesis of technetium and rhenium chelates as potential new radioimaging or radiotherapy agents. In the latter half of 2009, Dr. Schaffer returned to Canada to accept his new role as Deputy Head, and is now Head of the Life Sciences program at TRIUMF. He is responsible for maintaining TRIUMF’s medical isotope and radiotracer production programs in support of neurological and oncology research.
In response to the 2007-2009 99mTc supply crises, Dr. Schaffer and his collaborators spearheaded a successful effort to establish proof of concept commercial-scale, non-reactor production of 99mTc. This effort saw four institutions come together with funding from Natural Resources Canada (NRCan) to demonstrate direct production of this isotope using Canada’s existing medical cyclotron infrastructure. Dr. Schaffer is currently serving as founding CEO of ARTMS Products, Inc., a spin-off company looking to commercialize the technology developed through the NRCan-funded initiative. Under his direction, ARTMS was chosen as the winner of ‘Most Promising Pre-Commercial Technology’ at the 2017 BC Tech’s Technology Impact Awards.
For his leadership efforts, Dr. Schaffer was recognized by Business in Vancouver as one of British Columbia’s 2013 Top Forty under 40 individuals; recognizing him as an effective researcher with an ability to create teams that produce high-impact results on short time scales. The NRCan-ITAP team was also recently awarded the 2015 NSERC Brockhouse Prize for Interdisciplinary Research.
Dr. Schaffer continues to re-define the TRIUMF Life Sciences program by focusing on its core competencies and continues to connect the TRIUMF program with industrial and commercial interests. Dr. Schaffer is a leader, an entrepreneur and one of British Columbia's most promising talents.
Dr Rowan Swann joined Fusion-AstraZenca as a radiochemist II. Rowan began studying at McMaster University to fulfill a Master's degree in Chemical Biology under the supervision of Dr. John Valliant and Dr. Saman Sedeghi with a focus on synthesizing molecularly targeted photoacoustic imaging agents. 2024 promoted her PhD in Chemical Biology.
Rojin is working in regulatory affairs department at AstraZenca Bio-Pharmaceutical Company. Rojin started her chemical biology MSc program under supervision of Dr. Sadeghi on January 2022 at McMaster University. currently, her project focuses on synthesis and demonstrating the retrograde transport of 125I-NGF in Alzheimer’s disease model. She got her Master degree in 2024.
Dr. Daniel Hernández Valdés joined McMaster Radiochemistry Group (2021-23) as a postdoctoral researcher at McMaster University under the supervision of Dr. Saman Sadeghi. In 2023, Daniel joined Fusion-AstraZenca as a radiochemist II. Daniel studied Radiochemistry at the Higher Institute of Technologies and Applied Sciences (InSTEC), University of Havana. He received his PhD in Chemistry in 2020 from the University of Zurich. During this time, he worked under the supervision of Prof. Roger Alberto in the fundamental organometallic chemistry of technetium and rhenium and in artificial photosynthesis. His current research concerns topics related to new radiofluorination methods and the synthesis and evaluation of new potential radiopharmaceuticals of 99mTc.
Dr. Kevin Wyszatko is a scientist at CNL. He completed his Ph.D. in Radiochemistry Chemistry under the supervision of Dr. John Valliant and Dr. Saman Sadeghi. He enjoyed McMaster's Radiopharmaceuticals Program for its holistic approach to research and translation, where synthetic chemistry, protein biochemistry, radiochemistry and pharmaceutical biology combine to create novel radiopharmaceuticals for clinical translation.
My post-doctoral research in the Valliant group (2013-14) centered on developing radiolabeling methods with a rapid and efficient purification protocol which complemented my synthetic methodology graduate work and prepared me to pursue a career in the radiopharmaceutical industry.
Over the past 6 years I have worked as a research scientist first with the Centre for Probe Development and Commercialization and most recently with the for profit spin-off company Fusion Pharmaceuticals. My research has focused primarily on discovering new intellectual property around bifunctional chelates and linkers while working closely within a multidisciplinary team to develop new targeted alpha radiotherapeutics.
My PhD research project in the Valliant group (2011-2017) centered on the synthesis, stability and photophysical properties of [2 + 1] Re(I) and Tc(I) complexes derived from bipyridine type ligands and a series of imidazole derivatives were investigated as a means of identifying complexes suitable for creating targeted isostructural optical/nuclear molecular imaging probes. I am interested in radiopharmaceutical chemistry and in particular, development and optimization of novel molecular imaging probes.